Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteur:	Zonderland, G
Andere auteurs:	Tarsounas, M
Formaat:	Thesis
Gepubliceerd in:	2017

Gelijkaardige items

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
door: Tacconi, E, et al.
Gepubliceerd in: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
door: Eliana MC Tacconi, et al.
Gepubliceerd in: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
door: Zimmer, J, et al.
Gepubliceerd in: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
door: Ashwin Ragupathi, et al.
Gepubliceerd in: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
door: Tacconi, E
Gepubliceerd in: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
door: Ilirjana Bajrami, et al.
Gepubliceerd in: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
door: Staples Oliver D, et al.
Gepubliceerd in: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
door: Rebecca A. Dagg, et al.
Gepubliceerd in: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
door: Melinda E. Snitow, et al.
Gepubliceerd in: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
door: Giuseppa Augello, et al.
Gepubliceerd in: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
door: Xuexia Xie, et al.
Gepubliceerd in: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
door: Patricia A. Vignaux, et al.
Gepubliceerd in: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
door: Hagit eEldar-Finkelman, et al.
Gepubliceerd in: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
door: Sorin Hostiuc, et al.
Gepubliceerd in: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
door: Shicheng Yang, et al.
Gepubliceerd in: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
door: Tingting Du, et al.
Gepubliceerd in: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
door: Karolina N. Dziadkowiec, et al.
Gepubliceerd in: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
door: Tacconi, E, et al.
Gepubliceerd in: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
door: Qianye Yang, et al.
Gepubliceerd in: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
door: Zatreanu, D, et al.
Gepubliceerd in: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
door: Young Ou, et al.
Gepubliceerd in: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
door: Eliana MC Tacconi, et al.
Gepubliceerd in: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
door: Julieta Martino, et al.
Gepubliceerd in: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
door: Ata ur Rahman Mohammed Abdul, et al.
Gepubliceerd in: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
door: Diana Zatreanu, et al.
Gepubliceerd in: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
door: Yosuke Akiba, et al.
Gepubliceerd in: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
door: William B Barrell, et al.
Gepubliceerd in: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
door: Julieta Martino, et al.
Gepubliceerd in: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
door: Przemysław Duda, et al.
Gepubliceerd in: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
door: Salar Farokhi Boroujeni, et al.
Gepubliceerd in: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
door: Sin-Aye Park, et al.
Gepubliceerd in: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
door: Robert A. Smith, et al.
Gepubliceerd in: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
door: Robert A Smith, et al.
Gepubliceerd in: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
door: Martinez, Ana, 1961-, et al.
Gepubliceerd in: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
door: Xia Ding, et al.
Gepubliceerd in: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
door: Geoffrey I Shapiro, et al.
Gepubliceerd in: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
door: Melissa S Cline, et al.
Gepubliceerd in: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
door: Suggala Ramya Shri, et al.
Gepubliceerd in: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
door: Rosa Buonfiglio, et al.
Gepubliceerd in: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
door: David Ebuka Arthur, et al.
Gepubliceerd in: (2020-11-01)